Ocumension completes enrollment in China Phase III trial of dry eye drug OT-211

• Ocumension Therapeutics completed patient enrollment in a Phase III China trial of OT-211 for dry eye disease.
• Results have not been presented; the update covered enrollment completion rather than trial outcomes.
• The study enrolled 398 patients, positioning the program to move into data readout and potential regulatory submission steps in China.
• OT-211 is TRYPTYR acoltremon eye drops, a TRPM8 agonist already cleared in the US for dry eye signs and symptoms.
• The China program is run under an exclusive license from Alcon, supporting Ocumension’s commercialization rights in Chinese Mainland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260902-12316946), on September 02, 2026, and is solely responsible for the information contained therein.